Navigation Links
Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
Date:6/10/2008

ions can be found on the ADA Web site at http://www.diabetes.org.

"In our metabolic disease franchise we have evaluated more than 130 biological targets and identified more than 20 therapeutic targets that have the potential to offer new approaches to treat diseases, such as obesity and diabetes," said Jeffrey Jonas, M.D., Executive Vice President of Isis Pharmaceuticals. "Our research demonstrates the ability of antisense technology to quickly validate novel targets that provide exciting new approaches to treat metabolic diseases. In particular, obesity is an area where we feel our peripherally acting drugs rather than centrally acting drugs could have a profound impact on the activity and tolerability of anti-obesity therapy. Furthermore, our ongoing clinical studies with other antisense drugs provide evidence for the long-term safety of antisense drugs, making them an attractive possibility for the treatment of chronic diseases."

About SGLT2 and ISIS 388626

The sodium dependent glucose transporter type 2 (SGLT2) is the primary mechanism responsible for glucose re-absorption in the kidney. Decreasing SGLT2 function promotes glucose excretion to help reduce blood sugar levels, making it an attractive target for the treatment of diabetes. In preclinical studies, ISIS 388626 and other antisense inhibitors of SGLT2, effectively reduced target mRNA levels in several animal species, increased urinary glucose excretion and consequently lowered blood glucose levels and HbA1c (in hyperglycemic animals) without causing dangerously low levels of blood sugar known as hypoglycemia. These data are consistent with expectations based on human subjects who have mutations in the SGLT2 gene and have increased urine glucose levels but are otherwise asymptomatic. ISIS 388626 effectively and specifically inhibits the production of SGLT2 in the kidney tissue, without having any effect on a related gene product, SGL
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
2. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
3. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
8. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
9. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
10. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
11. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...v. 25 Praxis Electronic Medical Re...n Academy of Family Physicians, (AAFP) Family Prac...urvey for improving medical quality, health mainte...w ARRA Stimulus legislation. Praxis also ranked #1... effect in determining their salary. Finally, Prax...
(Date:11/25/2009)...5 ERT (Nasdaq: ERES ), ...Company,s President and CEO, and Keith Schneck, th...scheduled to present at the 21st Annual Piper Jaff...ber 1, 2009 in New York City, New York. ,, Inte...ting the Company,s corporate website at http://ww...
(Date:11/25/2009)... 25 Remedium Technologi... foam that stops severe bleeding, won first prize ...tegory of the Global Security Challenge 2009, comp...more than 100 entries from around the world, Remed...rity Summit conference held at the London School o...
Breaking Medicine Technology:Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Stryker Announces Agreements To Acquire Assets 6148 1Stryker Announces Agreements To Acquire Assets 6148 2Stryker Announces Agreements To Acquire Assets 6148 3Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 1Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 2Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 3Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 4Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 5Sanofi aventis and Regeneron Expand Strategic Antibody Collaboration 6144 6US Oncology Announces Retirement of General Counsel Phil Watts 14789 1US Oncology Announces Retirement of General Counsel Phil Watts 14789 2
...sults from placebo,controlled phase IIa study in p...SCHLIEREN (Zurich), Switzerland, May 15, 2007 - Cy...itive results from a multi-centre,and placebo-cont...,of CYT003-QbG10, an immunotherapeutic product can... study included 40 patients,suffering from mild to...
...at Least 24 Weeks, According,to Report Published i...Newswire/ -- Researchers from Guy,s,Hospital and K...nced the results from the first randomized, double...num toxin type A (BTX-A,BOTOX(R)) as a treatment ...ents with symptoms of overactive bladder (OAB). Th...
Other Medicine Technology:Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 2Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 3Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 4Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 5Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 6Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 7First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 2First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 3First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 4
(Date:11/29/2009)... Traditional healthcare,s uncerta...e affordable alternative care. Affordable Acupunct... (PRWEB) November 29, 2009 -- Affordable ...his year (2009) and has been met with enthusiasm a...success can be attributed to two things, need and ...
(Date:11/28/2009)...offer tips to help lift spirits, recognize signs o...thDay News) -- For many seniors, the holiday seaso...loved ones, struggle with health issues or worry a...iatrics Society. , To help overcome the seasona...fers the following advice: , Get out and sociali...
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 /PRNewswire-FirstCall/ -...ced that Blair Lambert, CFO/COO, will present at t... held at the May Fair Hotel in London, England, on..., To listen to a live broadcast of The Gymboree...ase log on to www.gymboree.com, click on "Our Comp...
(Date:11/27/2009)...and cycling plus low-emission vehicles may reduce ..., FRIDAY, Nov. 27 (HealthDay News) -- Encouraging...g cars would offer much greater public health bene... U.K. researchers have found. , The study compa...ative urban land transport scenarios for London, E...
(Date:11/27/2009)... Specialist manufacturers who use... are saving millions of dollars by bringing in tec...s. Increasing numbers of pro-active medical manufa...t the concept stage of their projects, ensuring th...sign processes or potentially outdated technology....
Breaking Medicine News(10 mins):Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...Hint of Sweetness Through Simple Ingredients , , ...mier natural food company, today announced the lau...ries pure ingredients with real vanilla to create ... delicate, unique flavor that Island Vanilla bri...
...h 31 /PRNewswire-Asia/ -- WuXi AppTec announced to... been inspected by the U.S. Food and,Drug Administ...hich is used to,report any non compliance issues a...shed in 2005. BAS provides,Good Laboratory Practic...
... Milliman,s fourth annual Guaranteed Living Benefi...VA) carriers revealed that about 96% of variable a...les of VAs that offered a GLB during calendar year...008 with 96% of total VA sales offering a GLB. , ...
... Certification Confirms MedL10N Division,s C...ijing, China (PRWEB) March 31, 2009 -- CSOFT Inter...localization, testing and outsourced software deve...n. This ISO certification specifies the necessary...
...h 31 /PRNewswire-Asia/ -- Tiens Biotech Group (USA...S: TBV), http://www.tiens-bio.com ,today announc...ended,December 31, 2008. , For the twelve mont... Net income for the twelve months ended Decembe...
...igh-grade refractory patients recruited in trial;,...e in one year-, , , BELLEVILLE, ON, March 31 /PRN...TSX: BNC), a research-based, technology-driven Can... in the treatment of non-muscle-invasive bladder c...
Other Medicine News:Health News:Kashi Company Expands With New Island Vanilla(TM) Biscuit Cereal 2Health News:WuXi AppTec Bioanalytical Services Unit Passes FDA Inspection 2Health News:Milliman Survey Says Variable Annuity Guarantees Dominate Annuity Products 2Health News:Milliman Survey Says Variable Annuity Guarantees Dominate Annuity Products 3Health News:CSOFT Earns ISO 13485:2003 Certification for Medical Device Industry 2Health News:CSOFT Earns ISO 13485:2003 Certification for Medical Device Industry 3Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 2Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 3Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 4Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 5Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 6Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 7Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 8Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 9Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 10Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 11Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 12Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 2Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 3
...fectly balanced, the patented Orion incorporates s...that illuminates brilliantly. The fully adjustabl...d to sit low on the brow, directing the spot along...osition the cable diagonally over the head, balanc...
Coronary Artery Perfusion Cannulae with Balloon
...PLETH is seven pounds of intelligent Pulse Oximete... software developed over 7 years by a dedicated R&...n saturation monitoring. The combination of unique...uration sensor designs using our exclusive SuperBr...
... ODISsey Tissue Oximeter is a lightweight, portabl...ay monitor with two separate channels for up to on... adjustable alarms for low and high limits for StO...quires minimal training., ,Sensors of differen...
Medicine Products: